Fed: Inflation has ‘made progress’ towards 2 per cent target but remains high

Biopharmaceutical company Fulcrum Therapeutics recently disclosed that by the end of 2025, its total holdings of cash, cash equivalents, and marketable securities will reach $352.3 million.

First Watch Restaurant Group recently announced its capital expenditure plan for fiscal year 2026, with a total investment expected to reach $150 millions to $160 millions.

Iovance Biotherapeutics recently announced plans to launch a single-arm registration clinical trial in the second quarter of 2026.

According to the latest guidance median forecast, the 2026 adjusted EBITDA of Enviri Corporation's two core businesses—Harsco Environmental and Harsco Rail—is expected to see a slight decline compared to 2025.